Aperio Group’s Teva Pharmaceuticals TEVA Stock Holding History

Aperio Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.19M	Sell	122,805 -134,522	-52%	-$1.29M	﹤0.01%	1498
2020 Q3	$2.32M	Sell	257,327 -10,269	-4%	-$109K	0.01%	1051
2020 Q2	$3.3M	Buy	267,596 +415	+0.2%	+$4.69K	0.01%	890
2020 Q1	$2.4M	Buy	267,181 +15,678	+6%	+$161K	0.01%	945
2019 Q4	$2.46M	Buy	251,503 +78,405	+45%	+$700K	0.01%	1002
2019 Q3	$1.19M	Buy	173,098 +49,641	+40%	+$380K	﹤0.01%	1309
2019 Q2	$1.14M	Sell	123,457 -88,210	-42%	-$1.06M	﹤0.01%	1346
2019 Q1	$3.32M	Sell	211,667 -47,815	-18%	-$843K	0.01%	839
2018 Q4	$4M	Sell	259,482 -105,095	-29%	-$2.15M	0.02%	725
2018 Q3	$7.85M	Sell	364,577 -1,643	-0.4%	-$38.1K	0.03%	524
2018 Q2	$8.91M	Buy	366,220 +74,131	+25%	+$1.51M	0.04%	475
2018 Q1	$4.99M	Buy	292,089 +30,860	+12%	+$603K	0.02%	660
2017 Q4	$4.95M	Buy	261,229 +88,374	+51%	+$1.33M	0.03%	645
2017 Q3	$3.04M	Sell	172,855 -20,061	-10%	-$451K	0.02%	785
2017 Q2	$6.41M	Buy	192,916 +17,634	+10%	+$546K	0.04%	504
2017 Q1	$5.63M	Sell	175,282 -17,273	-9%	-$589K	0.04%	507
2016 Q4	$6.98M	Sell	192,555 -316,142	-62%	-$12.6M	0.05%	404
2016 Q3	$23.4M	Buy	508,697 +54,213	+12%	+$2.83M	0.17%	142
2016 Q2	$22.8M	Buy	454,484 +17,510	+4%	+$932K	0.18%	134
2016 Q1	$23.4M	Sell	436,974 -3,071	-0.7%	-$180K	0.2%	118
2015 Q4	$28.9M	Buy	440,045 +56,542	+15%	+$3.49M	0.26%	83
2015 Q3	$21.7M	Buy	383,503 +37,414	+11%	+$2.43M	0.22%	109
2015 Q2	$20.5M	Buy	346,089 +51,966	+18%	+$3.21M	0.21%	112
2015 Q1	$18.3M	Buy	294,123 +50,279	+21%	+$2.92M	0.21%	113
2014 Q4	$14M	Buy	243,844 +39,546	+19%	+$2.2M	0.17%	138
2014 Q3	$11M	Buy	204,298 +14,350	+8%	+$760K	0.15%	169
2014 Q2	$9.96M	Buy	189,948 +11,933	+7%	+$610K	0.14%	183
2014 Q1	$9.41M	Buy	+178,015	New	+$8.23M	0.13%	185
2013 Q4	–	Sell	-137,804	Closed	-$5.43M	–	270
2013 Q3	$5.21M	Buy	137,804 +16,504	+14%	+$644K	0.1%	259
2013 Q2	$4.75M	Buy	+121,300	New	+$4.72M	0.11%	213

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Aperio Group's TEVA Position: Q4 2020 in Review

Aperio Group reduced its Teva Pharmaceuticals (TEVA) stake by 52% in Q4 2020, selling an estimated $1.29M and leaving 122,805 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

Aperio Group first reported a position in TEVA in Q2 2013 and has held it in 30 quarters since. The position peaked at $28.9M in Q4 2015. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

Aperio Group held 122,805 shares of Teva Pharmaceuticals worth $1.19M as of Q4 2020.
Aperio Group sold 134,522 Teva Pharmaceuticals shares in Q4 2020, an estimated $1.29M.
Teva Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1498 holding.
Aperio Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
Aperio Group's Teva Pharmaceuticals position peaked at $28.9M in Q4 2015.
450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.